GlobalData

#AI #AI / data analytics / healthtech / informatics #Big pharma #Drug development #Drug discovery #GlobalData

AI and big data will continue to disrupt pharmaceutical sector, says research

The Covid-19 pandemic has given businesses opportunity to implement technology-fuelled changes to the way they operate. AI and big data/analytics have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes, as well as marketing and sales, according to a survey… Read More

#Market Reports #News #Trending News #Trends & Analysis

#Clinical trials #Covid-19 #Data #GlobalData #Immunology / Virology & Vaccines

Covid-19 vaccine and therapeutic trials show different trends

Since Covid-19 was officially declared a pandemic by the World Health Organization (WHO), the peak in total number of clinical trials for the virus was seen in the month of April 2020. There has since been a steady decrease in new clinical trial investigations, except for the months of December… Read More

#News #Trends & Analysis

#Clinical trial #Diabetes #Drug development #GlobalData #Type 2 diabetes

Eli Lilly’s tirzepatide continues to outperform popular diabetes drugs

Eli Lilly’s tirzepatide, a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 receptor agonist (GLP-1RA), recently demonstrated that it was able to not only reduce HbA1c levels in type 2 diabetes (T2D) patients, but also confer weight loss when compared to insulin glargine in the SURPASS-4 trial. Tirzepatide… Read More

#News #Trends & Analysis

#Data #Diabetes #GlobalData #Research #Therapeutics

Global diabetes therapeutic market has grown sixfold in last 20 years

According to GlobalData, the diabetes market has gone through significant maturation, attributed to increased innovation and modernisation of therapeutic treatments over the past 20 years. The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to continue increasing in… Read More

#News

#Clinical trials #Depression #Drug development #GlobalData

Novel antidepressant has blockbuster potential

Following the news that the Food and Drug Administration (FDA) has accepted Axsome Therapeutics’ new drug application (NDA) for its novel antidepressant therapy AXS-05 and granted it priority review, GlobalData commented that it would be “a blockbuster drug” by 2026, estimating global sales of approximately US$1.3 billion by 2029. Philippa… Read More

#News #Trending News